Skip to main content
Industry News
Next-generation antibody startup BigHat raises $19M

BigHat Biosciences, a biotech startup working on what it calls next-generation antibodies for use in new therapies, raised $19 million in its Series A funding round. With the new capital it will continue development of its artificial intelligence-assisted antibody design platform.

Full Story: